Innovotech Inc. Announces Intention to Apply for Trading on the OTCQB Venture Market

(TheNewswire)

January 26, 2026 – TheNewswire - Edmonton,Alberta – Innovotech Inc. (TSXV: IOT, “Innovotech”, or the “Company”) announcesits intention to obtain a stock quotation in theUnited States and a trading symbol on the OTC Markets (“OTCQB”),an over-the-counter venture market.  A quotation on the OTCQB willenhance the Company’s visibility to the investment community withthe goal of making the Company more accessible to retail andinstitutional investors in the United States and to increase theliquidity of the Company.

The OTCQB quotation operates in parallel with theCompany’s primary Canadian listing.  The OTCQB quotation isexpected to impose no additional material compliance or reportingrequirements. As a foreign private issuer, Innovotech will continue tomeet its existing primary market disclosure obligations on SEDAR+,which satisfy OTC market requirements under established foreign issuerexemptions. To be considered for admission to the OTCQB, companiesmust meet certain financial standards, be current in their reportingobligations, and undergo an annual verification and managementcertification process.

In conjunction with the listing, the Company will alsoapply for eligibility with the Depository Trust Company("DTC"), enabling simplifiedelectronic clearing and settlement of its common shares for U.S.investors.

About Innovotech:

Innovotech Inc. is a Canadian boutique contractresearch organization specializing in advanced laboratory services andcommercializing proprietary technologies. A leader in biofilm science,the company provides expertise in antimicrobial testing,pharmaceutical analysis, and industrial laboratory solutions,supported by innovative methodologies and products includingits widely-used MBECAssay® kit for high-throughputantimicrobial and antibiotic testing. Innovotechserves clients across multiple sectors, delivering customized researchand testing services designed to meet rigorous regulatory andscientific standards such as those of the U.S. Food and DrugAdministration and Health Canada through its ISO-certified andGMP-accredited laboratories. Learn more at https://www.innovotech.ca.

Craig Milne, CEO          Innovotech Inc.

+1-604-239-1819        craig.milne@innovotech.ca

This document may containforward-looking statements that are predictive in nature and subjectto risks and uncertainties that cannot be predicted or quantified;consequently, actual results may differ materially from past resultsand those expressed or implied by any forward-looking statements.Factors that could cause or contribute to such risks or uncertaintiesinclude, but are not limited to: the regulatory environment includingthe difficulty of predicting regulatory outcomes; changes in the valueof the Canadian dollar; the Company’s reliance on a small number ofcustomers including government organizations; fluctuations inoperating results; government policies or actions; progress and costof clinical trials; reliance on key strategic relationships; uncertaintyrelated to intellectual property protection and potential costsassociated with its defense; the Company’s exposure to lawsuits andother matters beyond the control of management. Should known orunknown risks or uncertainties materialize, or should management’sassumptions prove inaccurate, actual results could vary materiallyfrom those anticipated. The Company undertakes no obligation topublicly make or update any forward- looking statements, except asrequired by applicable law.

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this release.

###

Copyright (c) 2026 TheNewswire - All rights reserved.